TD Cowen Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $36
Surgery Partners (SGRY) Poised for Upside: A Comprehensive Buy Rating Justification
Barclays Sticks to Their Hold Rating for Surgery Partners (SGRY)
Surgery Partners Analyst Ratings
Surgery Partners Analyst Ratings
Critical Insights From Surgery Partners Analyst Ratings: What You Need To Know
Surgery Partners Analyst Ratings
Surgery Partners' Growth Prospects Bolster Buy Rating
Surgery Partners (SGRY) Outperforms With Strong Q1 and Strategic Focus: A Buy Rating Maintained
Surgery Partners Analyst Ratings
Citigroup Maintains Buy on Surgery Partners, Lowers Price Target to $38
Surgery Partners: Strong Fundamentals and Market Trends Justify Buy Rating Amidst Favorable Growth Projections
Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Repare Therapeutics (RPTX) and Penumbra (PEN)
Surgery Partners (SGRY) Gets a Buy From RBC Capital
Barclays Sticks to Its Hold Rating for Surgery Partners (SGRY)
Analysts' Top Healthcare Picks: IDEAYA Biosciences (IDYA), Surgery Partners (SGRY)
Surgery Partners Analyst Ratings
Surgery Partners Analyst Ratings
Surgery Partners: A Buy Rating Amidst Underperformance and Growth Potential
Surgery Partners Analyst Ratings
No Data